Applicant, as named in the Orange Book

Stemline Therap

Next listed expiry: Orserdu on 5 Jan 2038. 1 products with live protection, 0 without.

Products with listed protection

Drug	Ingredient	NDA	Earliest generic entry	Basis
Orserdu · 2 strengths elacestrant hydrochloride	elacestrant hydrochloride	217639	5 Jan 2038	patent

No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.